Biogen made investors very nervous after it announced that it was choosing to add an additional 510 patients to its key trial into its Alzheimer’s medicine.
The decision to flood more patients into the trial was made after it apparently saw “increased variability” on the data from those receiving aducanumab.
It’s a bad time for potential treatments into Alzheimer’s, with a raft of companies recently throwing in the towel on key drugs since the start of the year and Pfizer surprising the entire industry by dumping its neuroscience division.
